What is Complexa?
Complexa Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from severe and life-threatening fibrotic and inflammatory diseases. The company's focus on these challenging conditions positions it within a critical area of unmet medical need, aiming to significantly improve patient outcomes through innovative scientific approaches.
How much funding has Complexa raised?
Complexa has raised a total of $90.1M across 10 funding rounds:
Private Equity
$2M
Series A
$3.6M
Debt
$1.4M
Private Equity
$200K
Series B
$14.8M
Debt
$4M
Debt
$950K
Debt
$1M
Series C
$62M
Debt
$150K
Private Equity (2012): $2M, investors not publicly disclosed
Series A (2012): $3.6M led by Pittsburgh Life Sciences Greenhouse
Debt (2013): $1.4M, investors not publicly disclosed
Private Equity (2013): $200K featuring Pittsburgh Life Sciences Greenhouse
Series B (2014): $14.8M backed by Pittsburgh Life Sciences Greenhouse
Debt (2015): $4M, investors not publicly disclosed
Debt (2016): $950K, investors not publicly disclosed
Debt (2016): $1M, investors not publicly disclosed
Series C (2017): $62M featuring Edmond de Rothschild Investment Partners, New Enterprise Associates, HBM Healthcare Investments, and JAFCO
Debt (2020): $150K backed by PPP
Key Investors in Complexa
Edmond de Rothschild Investment Partners
Edmond de Rothschild Investment Partners is a French investment banking firm with a long history, offering a wide array of financial services and solutions.
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm based in Menlo Park, California, known for its focus on supporting entrepreneurs in building successful businesses.
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded entity concentrating on the global healthcare sector, managing a diverse portfolio of both private and public companies to capitalize on industry growth.
What's next for Complexa?
The recent major strategic investment signifies a pivotal moment for Complexa, likely enabling the company to advance its lead drug candidates through crucial clinical trials and expand its research and development capabilities. This backing suggests confidence from investors in Complexa's therapeutic potential and its strategy to address complex fibrotic and inflammatory conditions, paving the way for potential commercialization and broader market impact.
See full Complexa company page
